- BUZZ - Waters shares rise after raising full-year forecast, third quarter results exceed expectations
- BUZZ-Onsemi rises on optimistic forecast and Ferric deal
- Updated version 2 - CVR Energy will acquire two refineries and marketing operations from Marathon for $4.2 billion.
- Pfizer raises its 2026 performance forecast due to strong demand for its anticoagulant Eliquis
- Hagerty Q3 2026 net income falls 21% to $36.27 million; revenue drops 10% to $354.24 million
- USA Compression Partners Q3 2026 net income jumps 37% year over year to $47.35 million; Q3 2026 total revenues rise 43% to $357.19 million year over year
- ANI Pharmaceuticals Presents at Guggenheim, Jefferies Healthcare Conferences
- CNO FINANCIAL GROUP, INC. <CNO.N>: BMO RAISES TARGET PRICE TO $58 FROM $52
- LUMENTUM HOLDINGS INC. <LITE.O>: BERNSTEIN CUTS TARGET PRICE TO $900 FROM $1220
- Ametek 3Q Net $426.3M >AME
- Ametek 3Q Adj EPS $2.21 >AME
- Ametek 3Q EPS $1.85 >AME
- FOX CORP <FOXA.O>: BERNSTEIN RAISES TARGET PRICE TO $74 FROM $73
- Pfizer raises 2026 revenue forecast to $62 billion-$64 billion
- ESTÉE LAUDER <EL.N>: TELSEY ADVISORY GROUP RAISES TARGET PRICE TO $116 FROM $108
- FLUTTER ENTERTAINMENT PLC <FLUT.N>: BERNSTEIN CUTS TARGET PRICE TO $100 FROM $110
- DRAFTKINGS INC. <DKNG.O>: BERNSTEIN CUTS TARGET PRICE TO $27 FROM $29
- Aptiv 3Q Sales $3.2B >APTV
- THE GAP, INC. <GAP.N>: BMO RAISES TARGET PRICE TO $24 FROM $23
- ESTÉE LAUDER <EL.N>: BERNSTEIN CUTS TARGET PRICE TO $109 FROM $114
- Vext Science Q3 net loss widens 86% to USD 4.88 million; Q3 revenue rises 18% to USD 14.9 million
- Pfizer appoints Cécile Cabanis as Chief Financial Officer
- Vext Science management commentary cites inventory costs, lower output as drivers of Q3 2026 margin decline
- Apollo Global Management reports adjusted earnings per share of $2.07 for the third quarter, below expectations
- Apollo Global Management’s third-quarter revenue was $4.739 billion, below expectations.
- REPUBLIC SERVICES INC <RSG.N>: BERNSTEIN RAISES TARGET PRICE TO $230 FROM $227
- GIBSON ENERGY INC. <GEI.TO>: BMO RAISES TARGET PRICE TO C$33 FROM C$31
- Kesko’s K-Rauta USB-Rechargeable Lighting Sales Double in January-September
- HII <HII.N>: BERNSTEIN RAISES TARGET PRICE TO $352 FROM $304
- BATH & BODY WORKS, INC. <BBWI.N>: BMO RAISES TARGET PRICE TO $24 FROM $20
- GENERAL DYNAMICS CORP <GD.N>: BERNSTEIN RAISES TARGET PRICE TO $386 FROM $365
- BRIEF-PJT Partners Q3 Revenue USD 385.1 Million Vs. IBES Estimate USD 431.5 Million
- PJT Partners Third-Quarter Net Income Falls 25% to $56.02 Million
- Protalix BioTherapeutics to Report Third-Quarter Financial Results
- PJT Partners 3Q EPS $1.15 >PJT
- TREX BIO, INC. <TRXB.O>: STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $39
- COPEL Completes Delisting From Latibex
- VERTEX PHARMACEUTICALS INCORPORATED <VRTX.O>: STIFEL RAISES TARGET PRICE TO $563 FROM $500
- Marathon Petroleum Q3 2026 net income attributable to MPC rises to $7.45 billion year over year
- Marathon Petroleum 3Q Refining & Marketing Adjusted Ebitda $9.9B >MPC
- COPEL Delists Shares From Latibex
- PHILIP MORRIS : STIFEL RAISES TARGET PRICE TO $232 FROM $205
- Pfizer management commentary cites non-COVID product growth as driver of Q3 2026 performance
- Pfizer raises 2026 adjusted diluted EPS guidance to $2.95-$3.05
- CVG swings to Q3 2026 net profit of $5.6 million year over year; Q3 2026 revenue climbs 37% year over year to $208.1 million
- LATTICE SEMICONDUCTOR CORPORATION <LSCC.O>: STIFEL RAISES TARGET PRICE TO $175 FROM $165
- Marathon Petroleum 3Q Adjusted Ebitda $11.7B >MPC
- Pfizer: To Continue to De-Lever Over Longer Term in Prudent Manner in Order to Maintain Balanced Capital Allocation Strategy >PFE
- Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2026 >PFE
- ICHOR HOLDINGS, LTD. <ICHR.O>: STIFEL CUTS TARGET PRICE TO $93 FROM $115
- HINGE HEALTH, INC. <HNGE.N>: STIFEL RAISES TARGET PRICE TO $135 FROM $130
- MPLX Q3 net income attributable to partnership falls 25% to $1.16 billion
- CIVEO CORP <CVEO.N>: STIFEL RAISES TARGET PRICE TO $42 FROM $37
- Aptiv Q3 2026 adjusted EBITDA falls 5% year-on-year to $567 million
- BUZZ-ON Semiconductor rises on upbeat forecast, Ferric deal
- BIOMARIN PHARMACEUTICAL INC. <BMRN.O>: STIFEL CUTS TARGET PRICE TO $66 FROM $70
- Pfizer Had Seen 2026 Revenue $60.5B-$62.5B >PFE
- Pfizer Had Seen 2026 Adjusted EPS $2.80-$3.05 >PFE
- ONEOK, INC. <OKE.N>: SCOTIABANK RAISES TARGET PRICE TO $97 FROM $96
- SOPHiA GENETICS Presents 25% Revenue Growth in Q3 2026
- SOPHiA GENETICS Q3 2026 net loss widens to USD 20.27 million; Q3 2026 revenue rises 25% to USD 24.27 million
- BioNTech Q3 2026 swings to net profit of €184.5 million
- DT MIDSTREAM, INC. <DTM.N>: SCOTIABANK CUTS TARGET PRICE TO $161 FROM $165
- BRIEF-Marathon Petroleum Q3 Adjusted EPS USD 26.93 Vs. IBES Estimate USD 24.5
- MPLX 3Q Net Income Attributable to MPLX of $1.2B >MPLX
- BRIEF-Pfizer Q3 Adjusted EPS USD 0.87 Vs. IBES Estimate USD 0.73
- Pfizer 3Q EPS 56c >PFE
- Pfizer Sees FY Adj EPS $2.95-Adj EPS $3.05 >PFE
- Pfizer Sees FY Rev $62B-$64B >PFE
- Marathon Petroleum 3Q EPS $26.59 >MPC
- Dynatrace Cuts FY27 View To Adj EPS $1.88-Adj EPS $1.90 Vs Prior View $1.97-$1.99 >DT
- --Earnings Flash (BNTX) BioNTech Posts Q3 Revenue 1.29B Euros, vs. FactSet Est of 1.03B Euros
- -- Earnings Flash (AME) AMETEK Posts Q3 Adjusted EPS $2.21 per Share, vs. FactSet Est of $2.11
- --GUIDANCE: (BNTX) BioNTech Expects 2026 Adjusted Revenue Range 1.70B Euros - 1.90B Euros, vs. FactSet Est of 1.80B Euros
- Ferrari Q3 Earnings, Revenue Rise; Raises 2026 Guidance
- Clarivate Q3 Adjusted Earnings Rise, Revenue Falls; Q4 Guidance Set
- --Earnings Flash (BNTX) BioNTech Posts Q3 Adjusted EPS 1.76 Euros
- Ideaya Biosciences Reports Q3 Loss
- Palantir Well Positioned to Benefit From AI Tailwinds Amid Accelerating Revenue Growth, Truist Says
- Patria Investments' Q2 Distributable Earnings Flat, Revenue From Services Increase
- Thomson Reuters Q3 Adjusted Earnings, Revenue Rise
- -- Earnings Flash (MPLX) MPLX Posts Q3 Net Income $1.15, vs. FactSet Est of $1.13
- -- Earnings Flash (PJT) PJT Partners Posts Q3 Adjusted EPS $1.41 per Share, vs. FactSet Est of $1.48
- -- Earnings Flash (PJT) PJT Partners Reports Q3 Revenue $385.1M, vs. FactSet Est of $409.7M
- --GUIDANCE: (PFE) Pfizer Expects 2026 Adjusted EPS Range $2.95 to $3.05, vs. FactSet Est of $2.96
- --Earnings Flash (IEP) Icahn Enterprises Posts Q3 Loss $0.31 a Unit
- Pfizer Names Cecile Guegan as Permanent CFO
- Fortis Q3 Adjusted Earnings Rise; Dividend Increases
- --GUIDANCE: (PFE) Pfizer Expects 2026 Revenue Range $62B to $64B, vs. FactSet Est of $62.24B
- TransAlta Swings to Q3 Adjusted Earnings, Revenue Falls
- -- GUIDANCE: (NPO) Enpro Expects Full Year 2026 Adjusted EPS Range $9.70 - $9.95, vs. FactSet Est of $9.59
- -- Earnings Flash (MPC) Marathon Petroleum Corporation Reports Q3 Revenue $56.03B, vs. FactSet Est of $46.61B
- -- Earnings Flash (MPC) Marathon Petroleum Posts Q3 Adjusted EPS $26.93 per Share, vs. FactSet Est of $25.37
- --Earnings Flash (CMPS) Compass Pathways Posts Q3 Loss $0.31 a Share, vs. FactSet Est of $0.39 Loss
- -- GUIDANCE: (NPO) Enpro Expects Full Year 2026 Revenue Range $1.33B - $1.34B, vs. FactSet Est of $1.32B
- -- GUIDANCE: (STVN) Stevanato Expects Full Year 2026 Revenue Range 1.26B Euro -1.28B Euro, vs. FactSet Est of 1.27B Euro
- -- Earnings Flash (MPLX) MPLX LP Reports Q3 Revenue $3.61B, vs. FactSet Est of $3.35B
- -- Earnings Flash (PFE) Pfizer Reports Q3 Revenue $16.58B, vs. FactSet Est of $15.85B
- Revvity Q3 Adjusted Earnings, Revenue Rise
- --GUIDANCE: (XHR) Xenia Hotels & Resorts Expects 2026 Adjusted FFO a Share Range $2.08 - $2.14, vs. FactSet Est of $2.06
